Answers are grounded in this paper and cite their sources.
Obesity, a widely established chronic disease, presents challenges in its treatment. Unfortunately, obesity is often accompanied with a multitude of chronic maladies that substantially elevate health risks. Thus, it is critical to promote weight management in order to hinder the development of severe complications and to improve the overall patient well-being. Several approaches exist to address this condition and induce weight loss. In addition to lifestyle adjustments by physical activity and dietary modifications, some emerging medications could provide promising results in achieving a reduction in weight. This report discusses the potential implementation of Glucagon-like peptide-1 receptor agonist (GLP-1-RA) as a therapeutic option for obesity. Specifically, it will examine the efficacy of GLP-1-RA in the promotion of weight loss in both diabetic and non-diabetic patients. Nevertheless, it is essential to highlight the potential side effects associated with the use of this drug.
No takes yet. Share an insight, caveat, or question.
Mohamed Omar (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: